From today's press release: "Additional ProNeura feasibility evaluations are ongoing in the area of chronic pain treatment with a peripherally acting Kappa opioid receptor agonist, and in the treatment of type 2 diabetes with currently approved peptides. "
From the "Pipeline" section of Cara Therapeutics website:
"Cara Therapeutics is developing the first peripherally acting kappa opioid receptor agonist (KORA) called CR845."